Serious adverse events were noted in 5% of all patients presenting to the ED with presyncope and in 2% of those discharged to home.
Presyncope is the sense of an impending loss of consciousness. Its clinical importance in the emergency department (ED) setting has not been studied extensively. Now, investigators in two Canadian EDs conducted a prospective cohort study to determine outcomes among presyncope patients and to determine physicians' ability to predict serious adverse events at 30 days.
Of 780 patients with outcome data, 5.1% experienced a serious adverse event, including death (0.3%), cardiovascular events (3.1%), and noncardiac events (1.8%). Of 740 patients discharged to home, 1.9% experienced serious outcomes after discharge. Physicians' ability to predict serious adverse events was very poor (area under the receiving operator characteristic curve, 0.58).
Reviewing Author
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals